Main points:
Review of sector Market:
This week (2.21 ~ 2.25), Shenwan beauty care sector rose by + 1.08%, stronger than the market. Shanghai Composite Index and gem index were – 1.13% and + 1.03% respectively. Shenwan beauty care sector outperformed Shanghai Composite Index by 2.21pct and gem index by 0.05pct.
Wind medical beauty and cosmetics index: this week, the CSI 300 index was – 1.67%, and the wind medical beauty index was + 0.63%, outperforming the CSI 300 market by 2.30pct; Wind cosmetics index + 0.12%, outperforming the Shanghai and Shenzhen 300 market by 1.79pct.
Industry highlights:
(1) Jingdong supermarket released the consumption trend report of 2022 goods Festival, which revealed the new consumption trend during the Spring Festival of the year of the tiger from the categories of personal care and Jiaqing. The report shows that the hair care market is further refined and high-end, and household cleaning products such as laundry beads and wet toilet paper maintain rapid growth. (CBO News)
(2) during the national cosmetics supervision and sampling inspection in 2021, the prohibited raw materials specified in the technical specifications for the safety of cosmetics (2015 Edition) were detected in 8 batches of cosmetics through the inspection of Xinjiang Uygur Autonomous Region Institute of drug inspection and other units. (State Food and Drug Administration)
Company announcement:
Bloomage Biotechnology Corporation Limited(688363) : the announcement of 2021 annual performance express was issued. During the reporting period, the company achieved an operating revenue of 4.95 billion yuan, an increase of 88% year-on-year; The net profit attributable to the parent company was 780 million yuan, an increase of 21% year-on-year; The net profit deducted from non parent company was 660 million yuan, with a year-on-year increase of 17%.
Huadong Medicine Co.Ltd(000963) : Sino US East China, a wholly-owned subsidiary of the company, signed a product exclusive license agreement with kiniksa, a wholly-owned subsidiary of kiniksapharmaceuticals, a US listed company. China, the United States and East China obtained two global innovative products arcalyst in the field of autoimmunity from kiniksa ® And mavrilimumab, including development, registration and commercialization rights and interests in 24 Asia Pacific countries and regions such as China, South Korea, Australia, New Zealand and India. China, the United States and East China will pay kiniksa a down payment of US $22 million, a milestone payment of up to US $640 million for development, registration and sales, and a graded double-digit net sales royalty.
Sihuan pharmaceutical: the anti hepatitis B virus drug propofol tenofovir fumarate tablets developed by Jilin Sihuan Pharmaceutical Co., Ltd., a subsidiary of the group, has obtained the drug registration approval issued by the State Drug Administration, which is deemed to have passed the consistency evaluation of the quality and efficacy of generic drugs.
Investment advice
(1) cosmetics industry: the supervision of all links in the cosmetics industry has been tightened, and the product quality has attracted more and more attention. In terms of channels, online traffic changes, and the shaking platform has gradually become a new beauty position. Strong products + strong brands bring the possibility of breaking the brand circle, and continue to pay attention to the head cosmetics brand with strong R & D ability and brand strength. Attention: [ Yunnan Botanee Bio-Technology Group Co.Ltd(300957) ] subdivide the leader in the field of sensitive muscle skin care; [ Proya Cosmetics Co.Ltd(603605) ] diversified high-quality brands; [ Shanghai Jahwa United Co.Ltd(600315) ] multi category development and continuous innovation to create new items; [ Guangdong Marubi Biotechnology Co.Ltd(603983) ] focuses on medium and high-end, with rich marketing and distribution channels; [ Syoung Group Co.Ltd(300740) ] strong operation capacity and gradual improvement of category structure;
(2) medical beauty industry: the demand side of the medical beauty industry continues to expand, the supply side products are more diversified, and the policy side strengthens the supervision of medical beauty institutions and medical beauty products. We are optimistic about upstream medical and American enterprises with class III medical device certificate and perfect product matrix layout and downstream medical institutions with long-term standardized operation. Attention: [ Bloomage Biotechnology Corporation Limited(688363) ] local hyaluronic acid raw material leader; [ Imeik Technology Development Co.Ltd(300896) ] Tongyan needle is heavily listed, and differentiation meets higher demand; [ Huadong Medicine Co.Ltd(000963) ] overall layout of medical beauty business; [ Shanghai Haohai Biological Technology Co.Ltd(688366) ] integration of R & D, production and sales; [Sihuan medicine] botulinum toxin + double antibody go hand in hand; Pay attention to Lancy Co.Ltd(002612) etc. of the layout of downstream medical and aesthetic institutions.
Risk tips
The risk of intensified industry competition; Uncertainty of industrial regulatory policies; Macroeconomic fluctuations, etc.
